Virtu KCG Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$206K Buy
+420
New +$184K 0.01% 2138
2017
Q1
Sell
-12,143
Closed -$4.46M 3637
2016
Q4
$4.46M Buy
12,143
+3,544
+41% +$1.35M 0.11% 83
2016
Q3
$3.46M Sell
8,599
-78
-0.9% -$31.3K 0.08% 144
2016
Q2
$3.03M Buy
8,677
+2,878
+50% +$1.11M 0.06% 175
2016
Q1
$2.09M Buy
5,799
+3,662
+171% +$1.51M 0.06% 253
2015
Q4
$1.16M Sell
2,137
-6,884
-76% -$3.73M 0.02% 732
2015
Q3
$4.2M Buy
9,021
+6,696
+288% +$3.6M 0.07% 177
2015
Q2
$1.19M Sell
2,325
-4,901
-68% -$2.39M 0.02% 719
2015
Q1
$3.26M Buy
7,226
+5,388
+293% +$2.28M 0.07% 212
2014
Q4
$754K Buy
+1,838
New +$723K 0.01% 1230
2014
Q3
Sell
-5,839
Closed -$1.96M 3975
2014
Q2
$1.65M Sell
5,839
-10,398
-64% -$3.08M 0.03% 674
2014
Q1
$4.88M Buy
16,237
+5,928
+58% +$1.83M 0.06% 265
2013
Q4
$2.84M Buy
10,309
+7,880
+324% +$2.27M 0.03% 458
2013
Q3
$760K Buy
+2,429
New +$639K 0.01% 1482

Other funds holding REGN

Virtu KCG Holdings's REGN Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2017: 420 shares worth $206K. The stake represents 0.01% of the portfolio and ranks #2138 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in REGN as recently as Q4 2016.

Virtu KCG Holdings first reported a position in REGN in Q3 2013 and has held it in 14 quarters since. The position peaked at $4.88M in Q1 2014. 604 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

  • Virtu KCG Holdings held 420 shares of Regeneron Pharmaceuticals worth $206K as of Q2 2017.
  • Regeneron Pharmaceuticals was a new Virtu KCG Holdings position in Q2 2017.
  • Regeneron Pharmaceuticals made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2138 holding.
  • Virtu KCG Holdings first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 14 quarters since.
  • Virtu KCG Holdings's Regeneron Pharmaceuticals position peaked at $4.88M in Q1 2014.
  • 604 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.